Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.51 |
| ▸ | CDK8 | P49336 | 10/20 | 0.49 |
| ▸ | CDK7 | P50613 | 2/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
| ▸ | CCND1 | P24385 | 1/20 | 0.49 |
| ▸ | CCNC | P24863 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | CCNH | P51946 | 1/20 | 0.49 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.49 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 2/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29747290 | 0.89 | CDK8 (0.49) | CDK8CDK7CCNT1CCND1CCNC | |
| SCHEMBL19867929 | 0.86 | CDK8 (0.52) | CDK8CDK7AXLBCL2BCL2L1 | |
| SCHEMBL25586384 | 0.85 | RIPK1 (0.46) | CDK8CDK7CCNT1CCND1CCNC | |
| SCHEMBL29403244 | 0.84 | RIPK1 (0.45) | CDK8CDK7CCNT1CCND1CCNC | |
| SCHEMBL29695658 | 0.83 | CDK8 (0.45) | CDK8CDK7CCNT1CCND1CCNC | |
| SCHEMBL30427883 | 0.81 | CTNNB1 (0.49) | CTNNB1KDRIRAK4 | |
| SCHEMBL1958280 | 0.78 | CTNNB1 (0.55) | CTNNB1PDPK1IKBKBCHUKIRAK4 | |
| SCHEMBL30428638 | 0.78 | CTNNB1 (0.44) | CTNNB1CDK8CDK7CCNT1CCND1 | |
| SCHEMBL30314253 | 0.78 | BCL2 (0.52) | BCL2BCL2L1 | |
| SCHEMBL29657421 | 0.78 | NAMPT (0.45) | CDK8CDK7CCNT1CCND1CCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11944631-B2 | Combination therapies | INFINITY PHARMACEUTICALS, INC. (US) | 2024-04-02 | — | — | US | claimed |
| EP-3897647-B1 | COMBINATIONS OF A HDM2-P53 INTERACTION INHIBITOR AND A BCL2 INHIBITOR AND THEIR USE FOR TREATING CANCER | NOVARTIS AG (CH) | 2023-11-01 | — | — | EP | claimed |
| EP-2435432-B3 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE IRELAND UNLIMITED CO (BM) | 2023-10-25 | — | — | EP | claimed |
| WO-2023161940-A1 | APOPTOSIS RELATED PROTEIN IN THE TGF-BETA SIGNALING PATHWAY (ARTS) MIMETIC COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF IN INDUCTION OF APOPTOSIS | CARMEL-HAIFA UNIVERSITY ECONOMIC CORPORATION LTD. (IL) | 2023-08-31 | — | — | WO | claimed |
| EP-3370775-B1 | COMBINATION OF BCL-2 INHIBITOR AND MEK INHIBITOR FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2023-04-19 | — | — | EP | claimed |
| EP-2632436-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | Abbvie Inc. (US) | 2013-09-04 | — | — | EP | claimed |
| EP-2613769-A1 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | Abbvie Inc. (US) | 2013-07-17 | — | — | EP | claimed |
| EP-2576546-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbvie Inc. (US) | 2013-04-10 | — | — | EP | claimed |
| WO-2012121758-A1 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC. (US) | 2012-09-13 | — | — | WO | claimed |
| WO-2012058392-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBOTT LABORATORIES (US) | 2012-05-03 | — | — | WO | claimed |
| EP-2435432-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2012-04-04 | — | — | EP | claimed |
| WO-2011149492-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | claimed |
| EP-2387559-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2011-11-23 | — | — | EP | claimed |
| WO-2010138588-A9 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-05 | — | — | WO | claimed |
| WO-2010138588-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | claimed |
| WO-2010083442-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-07-22 | — | — | WO | claimed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4735438-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| WO-2010138588-A9 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2010138588-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11944631-B2 | Combination therapies | BCL2, BAK1, BCL3 | CTNNB1 2003/4885CDK8 1119/4885CDK7 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.